Using 570,000 HLB Shares...Raising Funds Without Issuing New Shares

HLB Life Sciences will raise 30 billion won in funds by using its HLB shares.

HLB Life Science company logo image. HLB Life Science

HLB Life Science company logo image. HLB Life Science

View original image

The company announced that on the 12th, its board of directors resolved to enter into a price return swap (PRS) contract using 572,519 shares of HLB as the underlying asset. This corresponds to 0.43% of HLB's total number of issued shares. The counterparty to the contract is Korea Investment & Securities, and the reference price is 52,400 won per share. The contract period is one year.


A PRS is a derivative transaction structure in which a company signs a contract with a financial institution using shares it holds as the underlying asset, and at maturity settles the price difference arising from share price fluctuations. A key feature is that no new shares are issued, so there is no dilution of equity.


HLB Life Sciences has been seeking an independent growth strategy since its planned merger with HLB recently fell through. The company explained that this funding measure is intended to secure financial stability and obtain resources for mid- to long-term growth.



A company official stated, "This is part of our strategic financial management to secure financial flexibility by utilizing our existing assets," adding, "We will pursue improvement of our financial structure based on operating profit and the strengthening of our growth foundation."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing